Pharming Group N.V annual net debt
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V Net Debt Growth & History (PHAR)
Pharming Group N.V's net debt was −$127.6M for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$127.6M | −$102.6M | — |
| 2024 | 2024-12-31 | −$25.0M | $3.6M | — |
| 2023 | 2023-12-31 | −$28.6M | $145.4M | — |
| 2022 | 2022-12-31 | −$174.0M | −$3.0M | — |
| 2021 | 2021-12-31 | −$171.0M | $23.9M | — |
| 2020 | 2020-12-31 | −$195.0M | −$127.7M | — |
| 2019 | 2019-12-31 | −$67.3M | — | — |
Pharming Group N.V quarterly net debt
Q4.21
Q4.22
Q4.23
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$45.0M | −$81.2M | — |
| Q1 2026 | 2026-03-31 | $63.8M | — | — |
| Q4 2025 | 2025-12-31 | −$127.6M | −$102.6M | — |
| Q3 2025 | 2025-09-30 | −$1.4M | — | — |
| Q2 2025 | 2025-06-30 | $36.2M | — | — |
| Q4 2024 | 2024-12-31 | −$25.0M | $3.6M | — |
| Q4 2023 | 2023-12-31 | −$28.6M | $145.4M | — |
| Q4 2022 | 2022-12-31 | −$174.0M | −$3.0M | — |
| Q4 2021 | 2021-12-31 | −$171.0M | — | — |
Pharming Group N.V net debt trends
Over the last five fiscal years, Pharming Group N.V's net debt increased from −$195.0M to −$127.6M, a change of $67.4M. The latest reported quarter, Q2 2026, shows −$45.0M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...